October 4, 2011
(no image)
Nephrologists are in the position of overseeing the health of patients with inflammatory kidney diseases of unknown origin, autoimmune disorders, and acute and chronic kidney diseases of many etiologies. A nephrologist is a specialist consultant and the patients we see are often referred by family doctors and internal medicine physicians. Several doctors who routinely refer patients to me have unquestioningly accepted the idea that “vaccines are safe for everyone” and the “benefit outweighs the small risk.” They inquired about my reasoning to withhold vaccinations in sick kidney patients.
Until I did my own research, I was also uninformed and accepted vaccines as safe and effective. Doctors do not receive any education on vaccine composition and the potential adverse effects. In medical training, we were told that patients should receive the vaccine schedule, and were assured that vaccines are safe and effective, except perhaps in a very small minority of people – maybe one in a million.
Patients with acute and chronic illnesses are target groups to be heavily vaccinated even though vaccines have barely been tested for safety or long-term consequences in these populations. Most doctors and patients assume that vaccines are simply a solution of sterile saline and “dead” microorganisms. They are not aware of the manufacturing process to make a vaccine, the contents in the vial, or the potential risks of each component. Doctors wrongly assume that vaccines “protect” their patients from disease, without any adverse consequences on their health, and that vaccinated people won’t get that disease.
Other than vaccines, is there any other drug or biological, that is given across-the-board to all comers, without regard for health status, age, or risk of aggravating an existing illness? Given the conflict of interest among members of the major vaccine-promoting committees, vaccines fall into a category that deserves independent study by health care providers.
Every patient should be informed about the potential risks of vaccination and the lack of evidence that vaccines will not harm them over the long-term. Patients have a personal right to choose – and refuse. Their informed choices should be respected. But in order for them to be informed, the person informing them would have to be informed – and doctors are not informed.
Autoimmune and inflammatory considerations
Some of the causes of kidney disease are autoimmune, vasculitic (inflammation of blood vessels), and granulomatous (described below). There are many conditions labeled as “idiopathic”(cause unknown) in nephrology and many are inflammatory in nature. When will doctors make the connection between vaccination and these adverse events?
Here is a partial list of diseases that are “granulomatous,” involve the kidney and more frequently than not, the underlying cause is never known:
*Wegener’s granulomatosis
*Churg-Strauss disease
*Sarcoidosis
*Granulomatous interstitial nephritis
These diagnoses often carry very poor prognoses, and their treatments are very unpleasant and dangerous. Given the likelihood that vaccines can cause disease in vulnerable patients it is impossible to predict safety across the board, and it is even more difficult to know which patients will suffer the consequences of a vaccine. The risk-benefit ratio is not necessarily one of favor for vaccination, and our inflamed kidney patients should not be reassured that the vaccine is necessary and safe. Most people would rather choose getting the flu with the miniscule risk of its complications, than develop a vaccine-induced kidney ailment. But for an unidentifiable part of the population this choice cannot be made. Vaccination is like a game of roulette. Some people seem to tolerate it (at least for the first few weeks, and thereafter nobody knows) while others could become case reports in medical literature.
Medical Center Experience
I witnessed multiple patients who were stable for years with chronic kidney disease (CKD) deteriorate or relapse rapidly after the flu and/or pneumonia vaccines. Other doctors just assume that deterioration is what you expect in a person with chronic disease, so when they see it, they don’t connect it with a vaccine. Yet given how often it happens, if doctors asked questions about vaccines when renal patients suddenly and rapidly decline, and saw that it happens repeatedly, you would think that they would make the link. But they don’t. It is a mysteriously huge blind spot.
In the Winter of 2009, I treated multiple adult patients who required dialysis after receiving both seasonal and H1N1 vaccines and/or pneumonia vaccines. No other cause for their renal failure could be identified. Some patients stated that they became ill after their flu shot. Two of these patients died and one remained on dialysis.
On the other hand no patients were dialyzed, in my eleven years of service at this hospital, simply after a case of influenza. We can see patients develop renal failure during flu-like illnesses – but almost exclusively only if they are prescribed and take large doses of NSAID pain medicine(e.g., ibuprophen), Angiotensin-Converting Enzyme Inhibitors (blood pressure drugs), Angiotensin Receptor Blockers, and/or they were severely volume depleted (dehydrated).
When recently-vaccinated people present to the doctor with acute kidney failure, have not taken any other nephrotoxin, and have no other cause for the kidney failure, the vaccine must be seriously considered as having precipitated the problem. Yet physicians will go out of their way to deny the vaccine as culprit even after they fail to find any other underlying cause. They have no problem admitting that other drugs cause kidney disease, but seem to have a reflex to deny a vaccine as problematic. Could this be from the sound-bites they have heard over and over – about vaccines being safe?
“In general, vaccinations should be deferred when a precaution is present. However, a vaccination might be indicated in the presence of a precaution because the benefit of protection from the vaccine outweighs the risk for an adverse reaction. This is left to the healthcare provider to make a decision. The following are precautions for TIV:
- Presence of a moderate or severe acute illness with or without a fever. Persons who were hospitalized with an acute illness but who are now well enough to be discharged from a hospital can be vaccinated.”
This recommendation leaves loopholes to vaccinate just about anyone, but is there any science to defend it? How could the benefit of vaccinating a severely-ill patient, or a patient who has organ impairment (and may not mount a significant antibody response anyway) outweigh the risk? Why is there such a rush to vaccinate all hospital patients even though any potential protection will not be present for weeks? Could it have more to do with medical policy and reimbursement than with what is in the best interest of a sick patient?
As doctors, this CDC recommendation isn’t adhered to, because before we evaluate a patient, vaccines have already been given by nurses and others who have no medical mandate. This often occurs on the first hospital-day, not when they are “well enough to be discharged.” My efforts to change the hospital vaccine policy to wait until discharge was categorically refused by the administration and hospital policy makers – at a meeting that I was not permitted to attend.
Patients are routinely given influenza and pneumonia vaccines on their first day of hospitalization; after a major surgical procedure; during an acute illness (like kidney failure, lymphoma, pneumonia, infections, auto-immune diseases, heart attacks) and often before a full diagnosis has been made.
In many cases, I would try to cancel or defer vaccinations using a written order, but was thwarted because a nurse had already injected the patient with a vaccine ordered by the pharmacist- via a standing hospital policy. I found this unacceptable, and my effort to adjust the inpatient vaccination policy of the hospital was futile.
These vaccines can harm patients who are already ill, especially renal patients. While the nephrologists are left trying to figure out the cause of the patient’s renal failure, any vaccine can make the inflammatory reactions already occurring in the kidney worse.
It is well-accepted that renal vulnerability to inflammatory and drug insults can stem from diabetes, concomitant kidney-toxic drugs, myeloma, recovering acute kidney injury, or an existing, but as yet undiagnosed renal disease. Giving vaccines as soon as a patient is admitted to the ward makes no logical scientific sense, and makes it much harder for doctors to diagnose the admitting problem. Needless vaccination is a liability issue for the doctor and the hospital that must be carefully reviewed.
Peer-Reviewed Literature
Increased awareness will only happen if doctors and hospitals are open to the likelihood of vaccine reactions in their patients, and are taking an accurate vaccine history. They must consider the possibility of a vaccine reaction occurring weeks to months after a vaccine, since this time period is rational – and since vaccine events have not been studied for auto-immunity over such a time frame. The burden of proof still rests upon the vaccine manufacturers and advisory groups who have neglected to do long-term studies, yet still tout vaccines as an acceptable preventative in the chronically ill, based on limited scientific information.
I have spent the past few years reading much of the available literature on the safety of vaccines – both conventional and alternative. None of these studies can convincingly conclude that vaccines are safe or protective. None discuss the safety of injecting two vaccines on the same day into a patient with acute or chronic kidney disease. If a patient with new-onset kidney failure gets a vaccine and does not recover kidney function, how can anyone be certain that recovery would not have taken place without a vaccine? The assumption is always that the vaccine had nothing to do with the poor outcomes.
Immune-complex glomerulonephritis and renal vasculitis are very serious types of inflammatory disorders. They are difficult to treat, and the patients find the suppressive treatments very stressful, both physically and emotionally. For this reason, doctors should consider the possible adverse outcomes or jeopardized renal recovery after injecting antigens, adjuvants, detergents, stealth viruses and preservatives into patients with these illnesses.
A review of the research often concludes that vaccines can be given “safely” to all renal patients, no matter what their chronic illness may be. These same studies only follow a very small numbers of patients for 4-6 weeks. These articles show that many of the test subjects were taking NSAIDS, corticosteroids, methotrexate or rituximab, a powerful monoclonal anti-B-cell antibody. They suggest that adequate antibody response can be achieved in chronically-ill persons, but rarely if ever discuss the relapse or exacerbation rate of the original disease after the vaccine is given. The immune-suppressing drugs in these studies may very well mask acute inflammatory vaccine reactions leading the analysis of the vaccine effect to be negligible. But who can extrapolate the effect on long-term remission after a vaccine has been given and the drugs are tapered? Vaccination studies do not follow subjects looking at decline in kidney function from normal kidneys or already- injured kidneys, subsequent inflammatory disorders, or reactivation of renal inflammatory disorders after being in remission for years. Nor do they assess the rate of myocardial infarctions, strokes, and cancer. None of these articles can convincingly conclude that vaccines are safe or protective in the chronically ill.
Thus, there are other important aspects of immunity that remain complete unknowns when it comes to vaccinations and the peer-reviewed literature. It is a leap of faith to assume that immunity can be reliably replicated solely by the crude process of inducing a temporary antibody through vaccination.
Efficacy of Influenza Shots in Adults
A study that shows a treatment approach to be “efficacious” means that the study produced good outcomes in a controlled experimental trial, often in highly-constrained conditions. Translating efficacious practices to routine practice settings to produce effective results (i.e., results that show protection in the face of the disease, or “effectiveness”) is one of the more challenging issues of evidence-based practice.
Efficacy in the vaccine literature is usually measured as antibody production at a desired titer. The assumption that an antibody titer of 1:40 is protective and translates into effectiveness is nothing more than an educated guess and far from a scientifically-established truth. Here are some examples of the statements made by leading investigators and drug companies about influenza titers and presumed protection:
Efficacy of Influenza Shots in Adults
A study that shows a treatment approach to be “efficacious” means that the study produced good outcomes in a controlled experimental trial, often in highly-constrained conditions. Translating efficacious practices to routine practice settings to produce effective results (i.e., results that show protection in the face of the disease, or “effectiveness”) is one of the more challenging issues of evidence-based practice.
Efficacy in the vaccine literature is usually measured as antibody production at a desired titer. The assumption that an antibody titer of 1:40 is protective and translates into effectiveness is nothing more than an educated guess and far from a scientifically-established truth. Here are some examples of the statements made by leading investigators and drug companies about influenza titers and presumed protection:
While there are thousands of published studies on different aspects of the influenza vaccines, the results are widely variable as are the study designs. But underlying most of them is an assumption that a titer of 1:40 protects; not a fact, proof or truth. This must be taken into consideration when making sweeping statements about the efficacy and effectiveness of influenza vaccines.
Effectiveness would be a preferred end point in a study since it is more reflective of reality than the constraints in an efficacy study. While the media hype and policy-making medical boards report on the safety and effectiveness of flu vaccines, this simply has never been proven. Cohort studies examining the rates of influenza disease and morbidity in the vaccinated vs. the unvaccinated are scarce.
I have consulted on cases of acute hospital-acquired renal failure that developed within 24 hours of a newly marketed “high-dose Fluzone” vaccine in ill patients who had slightly-impaired kidneys at the time of vaccine administration. In these cases the kidney function plummeted abruptly after the vaccines. There is NO data to support such a vaccination practice. In addition, the package insert of the flu vaccine and the CDC documents admit “Data from clinical trials comparing Fluzone to Fluzone High-Dose among persons aged 65 years or older indicate that a stronger immune response (i.e., higher antibody levels) occurs after vaccination with Fluzone High-Dose. Whether or not the improved immune response leads to greater protection against influenza disease after vaccination is not yet known.” Thus, effectiveness for this particular vaccine is completely unknown and efficacy is measured by an antibody. And, as always, there is no data on carcinogenicity or renal safety.
Hazardous Components in Pneumonia and Influenza Vaccines
The effects of the various toxic components in vaccines, such as formaldehyde and thimerosal in influenza vaccines, and phenol in the adult pneumonia vaccines, have been poorly studied in the medical literature, but the toxic levels are well documented by the Environmental Protection Agency (EPA).
Several commonly-used influenza vaccines still contain mercury in the form of thimerosal. Mercury is a known neurotoxin and nephrotoxin, which contributes to hypertension, immunosuppression, renal tubular necrosis, renal failure, anemia, proteinuria and a host of other illnesses. The multidose vial of Fluzone, manufactured by Sanofi-Pasteur, contains 25 mcg of thimerosal in each adult dose. The cumulative effect of annual mercury-containing vaccines, from childhood through adult life, cannot promote health and its neurotoxicity and nephrotoxicity are very real risks.
The original polio vaccines were made from infected neural tissue. It was deemed too risky to use such tissue for human vaccines, due to the possibility of inducing encephalitis and severe anaphylactic reactions. Instead, monkey kidney tissue was chosen and is still used for polio vaccine and vaccinia vaccine(smallpox) manufacture. Early on, in the 1950’s concern was raised over the possibility that antigens from monkey kidney tissue would pose a risk for nephritis in children injected with residual monkey kidney cells from vaccines. Today’s polio and smallpox vaccine ingredients still list “monkey kidney tissue.” To date, no adequate long-term studies have put this concern to rest. As seen above, nephritis can occur months to years after vaccination. Since nephritis is a low-incidence condition, a large sample of vaccinated and unvaccinated children would need to be followed, for a period of months to years, to adequately rule out the higher incidence of nephritis in polio-vaccinated children.
Polyoma viruses
When a patient does not recover after a treated episode of glomerulonephritis it is always assumed that the treatment simply didn’t’ work, but is it possible that the kidneys fail due to a reactivated latent kidney virus? Much more research is needed in order to understand the potential consequences of polyoma virus infection in patients treated for auto-immune diseases with steroids and cytotoxic agents aimed at purposefully impairing the immune cells of the body.
The FDA issued a statement reinstating the rotavirus vaccines from both companies for ingestion in infants, citing the benign nature of the virus in humans. This proclamation was made without any research into the effect a pig virus can have on infants, now or in the future. Any correlation between vaccine contaminants and cancers or wasting disease, especially in the immunosuppressed, will remain unknown and unstudied.
Immunity to responsibility
In 1986, a law was passed that exempted Pharmaceutical companies and doctors from any liability after a vaccine adverse event. “No vaccine manufacturer shall be liable in a civil action for damages arising from a vaccine-related injury or death.” (Public Law 99-660) At that time a fund was established which is filled by tax-payer money. This fund is designed to compensate the most severe cases. Patients whose chronic inflammatory issues are worsened by vaccines do not qualify.
In 2010 the US Supreme Court ruling in the case of Bruesewitz et al. v. Wyeth LLC, set a new precedent that further pads the vaccine manufacturers. The decision stated that vaccines are “unavoidably unsafe.”
Summary
All healthcare providers involved with the care of renal patients should evaluate the true risk of the vaccine vs. the benefit of overall health. This needs to be done by taking into consideration the broad array of information available. Those who do this will undoubtedly be surprised at what they find when addressing the topic thoroughly, with an open mind, realizing that there is not one single drug or procedure that they routinely give to all their patients, six months of age and older, every year of life.
Many patients are fearful of repercussions from providers for refusing vaccines. Health care providers should be caregivers and informed consultants, not dictators. Patients deserve to have their long-term health carefully considered with information that encompasses more than “protocols” and CDC guidelines that have no consideration for each individual’s health or need. Health care providers are not mandated to push the issue of vaccination, and they are hopefully bound to their oath to do no harm.
In today’s environment, health care providers have unfortunately become glorified slave- technicians rather than free-thinking, intellectual advocates of health. As we can see here, at the very least for kidney patients, vaccination recommendations and assumptions have outpaced their science base. It therefore rests on the shoulders of health care providers who wish to give the best possible care, to individualize treatment for those patients for whom data is absent, incomplete or questionable. Physicians are free to individualize medical care and that includes vaccination, but in order to do so they must independently research the very real risks involved in assembly-line vaccination.
Figure 1.
(no image)
References:
[1] Ratner H.,1988, “An Untold Vaccine Story,” Child and Family. vol 20:50-59 uscl.info/edoc/doc.php?doc_id=93&action=inline Dr Herbert Ratner was a voice of reason during the dangerous Salk vaccine campaign starting in 1954, that caused poliomyelitis outbreaks, the most famous being the “Cutter Incident.”
[2] Roman Bystrianyk, healthsentinel.com. See figure 1.
[3] –Korzeniowska-Kowal A. et al., 2001 “Molecular mimicry of bacterial polysaccharides and their role in etiology of infectious and autoimmune diseases.” PostepyHig Med Dosw. 55(2):211-32. PMID 11468971 –Orbach H. et al., 2010 “Vaccines and autoimmune disorders.” Discov Med. Feb;9(45)90-7. PMID 20193633
[4] Agmon-Levin N. et al.,2009 “Influenza vaccine and autoimmunity.” Isr Med Assoc J. Mar;11(3):183-5. PMID 19544711
[5]Liuba P. et al., 2007”Residual adverse changes in arterial endothelial function and LDL oxidation after a mild systemic inflammation induced by influenza vaccination.” Ann Med. 39(5):392-9. PMID 17701480
Tsai MY et al.,2005 “Effect of influenza vaccine on markers of inflammation and lipid profile.” J Lab Clin Med. June: 145(6): 323-27. PMID 15976761
Posthouwer D. et al. 2004 “Influenza and Pneumococcal Vaccination as a model to assess C-reactive protein response to mild systemic inflammation.” Vaccine. Dec 2;23(3);362-5. PMID 15530681
[6] Tishler M. Shoenfeld Y., 2004 “Vaccination may be associated with Autoimmune Diseases.” Isr Med Assoc J, Jul;6(7):430-2. PMID 15274537
[7] Agmon-Levin N. et al., 2009 “Vaccines and autoimmunity.” Nat Rev Rheumatol. Nov;5(11):648-52. PMID 19865091
[8] Bijol V. et al., 2006 “Granulomatous Interstitial Nephritis: A Clinicopathologic Study of 46 cases from a single institution.” Int J Surg Pathol. 14(1): 57-63. PMID 16501836.
[9] Vaideeswar P. Mittal BV., 2001 “Idiopathic necrotising granulomatous interstitial nephritis.” J Postgrad Med, April-Jun;47(2):111-2
[10]Pasquet F. et al., 2010 “Granulomatous interstitial nephritis: A retrospective study of 44 cases.” Rev Med Interne. Oct;31(10):676-6. PMID 20605281
–Joss N. et al., 2007 “Granulomatous interstitial nephritis.” Clin J Am Soc Nephrol. Mar;2(2):222-30. PMID 17699417.
[11] Bordet AL., 2001 “Post-vaccination granuloma due to aluminum hydroxide.” Ann Pathol. Apr;21(2):149-52.
[12] Seasonal Influenza Vaccine Safety: A Summary for Clinicians http://www.cdc.gov/flu/professionals/vaccination/vaccine_safety.htm
[13] . Yanai-Barar, et al. 2002 “Influenza vaccination induced leukocytoclastic vasculitis and pauci-immune crescentic glomerulonephritis.” Clinical Nephrology, Vol 58. No. 3.
–Damjanov, Ivan, 1979 “Progression of Renal Disease in Henoch-Schonlein Purpura After Influenza Vaccination.” JAMA, vol. 242, No.23. p2555-2556.
–Ulm, S. et al., 2006 “Leukocytoclastic vasculitis and acute renal failure after influenza vaccination in an elderly patient with myelodysplastic syndrome.” Onkoligie, vol. 29, No. 10, 470-2.
–Tavadia, S., 2003 “Leukocytoclastic vasculitis and influenza vaccination.” Clin Exp Dermatol., vol 28, No 2, 154-6.
–Kielstein, JT. 2000 “Minimal Change nephrotic syndrome in a 65-year-old patient following influenza vaccination.” Clin Nephrol, vol 54, no 3, 246-8.
–Narendran, A., 1993 “Systemic Vasculitis following influenza vaccination—report of 3 cases and literature review.” J Rheumatol, vol 20, no 8, 1429-31.
–Kelsall, J., 1997 ”Microscopic Polyangiitis After Influenza Vaccination.” J Rheumatol, vol. 24:6, 1198-1202
[14] Clajus, C. et al., 2009 “Minimal change nephrotic syndrome in an 82 year old patient following a tetanus-diphteria-poliomyelitis-vaccination.” BMC Nephrology, Aug, 10:21.
[15] Morbidity and Mortality Weekly Report (MMWR) is a weekly epidemiological digest for the United States published by the Centers for Disease Control and Prevention
[16] Vogtlander, NP et al., 2004 “Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients.” Vaccine, Jun 2;22(17-18):2199-201. PMID: 15149777.
[17] MMWR report, November 12, 2009 / 58(Dispatch);1-4. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm58d1112a1.htm
[18] Harnden A. et al., 2006 “Whooping cough in school age children.” BMJ Jul 22;333(7560):174-7. PMID 16829538
[19] Weir Jerry P.,”Use of Surrogate Markers of Efficacy.”Presentation for the FDA. Weir is the Director of division of viral products/CBER/FDA. www.fda.gov/downloads/BiologicsBloodVaccines/…/ucm090498.pdf
[20] FluLaval package insert.
[21] Clark T. et al.,2009. “Trial of 2009 Influenza A Monovalent MF59-Adjuvanted Vaccine.”NEJM.361:2424-2435. PMID 19745215.
[22] Ibid. Jerry Weir.
[23] Meeting Report. 2008. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10–11, 2007. Vaccine. Aug 12;26(34)4299-4303. PMID 18582523.
[24] Manzoli L. et al.,2009 “Influenza vaccine effectiveness for the elderly: a cohort study involving general practitioners in Abruzzo, Italy.” J Prev Med Hyg Jun;50(2)109-12. PMID 2009941
[25] –Brydak LB and Machala M., 2000 “Humoral immune response to influenza vaccination in patients from high risk groups.” Drugs Jul:60(1):35-53. PMID 10929929.
–Stiver, H Grant et al. 1977 “Impaired Serum Antibody Response to Inactivated Influenza A and B Vaccine in Renal Transplant Recipients.” Infection and immunity June ;16(3)738-41. PMID 330394.
–Cappel, R et al., 1983 “Impaired Humoral and Cell-Mediated Immune Response in Dialyzed Patients after Influenza Vaccination.” Nephron 33(1): 21-5. PMID 6188069.
[26] Occupational Health And Safety http://www.ccohs.ca/oshanswers/chemicals/chem_profiles/formaldehyde/health_for.html
[27] Zeliger, Harold.,2008 “Human toxicology of chemical substances.” William Andrew Press. ISBN-10: 1437734634
–Toxicological Review of Formaldehyde Inhalation-Assessment. 2010 “Quantitative Assessment, Major Conclusions in the Characterization of Hazard and Dose Response, and References.” www.epa.gov/iris http://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=223614
[28] National Cancer Institute. Formaldehyde and Cancer Risk. http://www.cancer.gov/cancertopics/factsheet/Risk/formaldehyde
[29] International Agency for Research on Cancer (June 2004). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 88 (2006): Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol. Retrieved May 4, 2009, from: http://monographs.iarc.fr/ENG/Monographs/vol88/index.php
[30]Occupational Safety and Health Guideline for Phenol. http://www.osha.gov/SLTC/healthguidelines/phenol/recognition.html
BREAST CANCER & THE ENVIRONMENT RESEARCH CENTERS. Early Life Exposure to Phenols and Breast Cancer Risk in Later Years FACT SHEET on PHENOLS. http://www.zerobreastcancer.org/research/bcerc_factsheets_phenols.pdf
[31] Harris R. et al., 1966 “Contaminant viruses in two live virus vaccines produced in chick cells.” Journal of Hygiene Mar;64: 1-7. PMID 4286627. –Starke G. et al.,1968 “On the problem of foreign viruses in viral vaccines produced on the chick embryo base.” Pharmazie Dec;23(12):669-78. PMID 4304716.
[32] McReardon B., “What’s coming through that needle? The problem of pathogenic vaccine contamination.” Fully referenced on line document: http://www.vaclib.org/sites/vac_coming_thru.html
[33] Li RM et al, 2002 “Molecular identification of SV40 infection in human subjects and possible association with kidney disease.” J Am Soc Nephrol Sep;13(9):2320-30. PMID 12191976.
[34] Dr Keerti Shah, a veteran SV40 scientist stated this in a workshop at the NIH January 27th 1997. Simian Virus 40(SV40): A possible human polyomavirus workshop. Page 30 of transcript.
[35] Rizzo P., 1999 “Unique Strains of SV40 in Commercial Poliovaccines from 1955 Not Readily Identifiable with Current Testing for SV40 Infection.” Cancer Res Dec 15(24):6103-8. PMID 10626798.
[36] Bookchin and Schumacher, “The Virus and The Vaccine.” St. Martin’s Griffin (June 23, 2005). ISBN 0312342721
[37] Rollison DE et al.,2004 “Case-control study of cancer among US Army veterans exposed to simian virus 40-contaminated adenovirus vaccine.” Am J Epidemiol Aug 15;160(4):317-24. PMID 15286016.
–Richmond JE et al.,1984 “Characterisation of a polyomavirus in two foetal rhesus monkey kidney cell lines used for the growth of hepatitis A virus.” Arch Virol 80(2-3):131-46. PMID 6326710.
[38] Bookchin and Schumacher, “The Virus and The Vaccine.” St. Martin’s Griffin (June 23, 2005). ISBN 0312342721
[39] Chen and Li RM et al., 2002 “BK Virus and SV40 Co-Infection in Polyomavirus Nephropathy.” Transplantation Dec 15;74(11) 1497-1504. PMID 12490781.
[40] Chen CH et al., 2010 “High Incidence of Malignancy in Polyomavirus-Associated Nephropathy in Renal Transplant Recipients.” Transplantation Proceedings, Apr;42(3),817-18. PMID 20430180.
[41] Ibid.
[42] Aoki K et al., 2010 “Acute renal failure associated with systemic polyoma BK virus activation in a patient with peripheral T cell lymphoma.” Int J Hematol. Nov;92(4):638-41. PMID 20924732.
[43] Ibid. Shah.
[44] Ibid. Li RM.
[45] Ma H. et al., 2011 “Investigations of porcine circovirus type 1 (PCV1) in vaccine-related and other cell lines.” Vaccine Aug 8.